BTG, a company based in London, UK, won European CE Mark clearance for its DC Bead LUMI radiopaque drug-eluting bead. This is the first such device available in Europe.
The beads can be loaded with either doxorubicin or irinotecan, commonly used chemo agents, and injected into tumors within the liver. Their radiopaque quality, thanks to a compound called tri-iodobenzyl, allows these devices to be tracked using standard CT scans, confirming their correct placement.
“The ability to see bead location during TACE procedures is a key step in enhancing the quality and potentially minimising complications of the procedure, and can help improve treatment outcomes compared to current techniques,” said PD Dr Tobias Jakobs, The Hospital of the Order of St. John of God, Munich, Germany, in a published statement. “More importantly, the lasting radiopacity of DC Bead LUMI™ means I can show patients that treatment has been placed exactly where it’s needed.”
Product page: DC Bead LUMI…
Via: BTG…